ContraFect Corp (CFRXQ) USD0.0001

Sell:$0.00Buy:$0.00No change

Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase, is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its exebacase is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

Key people

Click to see more

Key facts

  • EPIC
    CFRXQ
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US2123264093
  • Market cap
    $2,140.00
  • Employees
    23
  • Shares in issue
    10.70m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.